Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 17;14(10):2468. doi: 10.3390/cancers14102468

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure A5 — Effectiveness of 2L lapatinib following a 1L trastuzumab-containing regimen. (A) TTNT or death; (B) OS. 1L = first-line; 2L = second-line; CI = confidence interval; NE = not estimable; No = number; OS = overall survival; P = pertuzumab; P+ = pertuzumab-exposed; rwPFS = real-world progression-free survival; TTNT = time to next relevant treatment.

Figure A5 — Effectiveness of 2L lapatinib following a 1L trastuzumab-containing regimen. (A) TTNT or death; (B) OS. 1L = first-line; 2L = second-line; CI = confidence interval; NE = not estimable; No = number; OS = overall survival; P = pertuzumab; P+ = pertuzumab-exposed; rwPFS = real-world progression-free survival; TTNT = time to next relevant treatment.